Reinforcing Therapist Performance (RTP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01016704|
Recruitment Status : Completed
First Posted : November 19, 2009
Last Update Posted : July 27, 2011
|Condition or disease||Intervention/treatment||Phase|
|Substance Use||Behavioral: Incentive||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||105 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||Reinforcing Therapist Performance|
|Study Start Date :||November 2008|
|Actual Primary Completion Date :||June 2011|
|Actual Study Completion Date :||June 2011|
|No Intervention: Control|
Participants assigned to the experimental condition are reinforced via monetary incentives for demonstrating superior delivery of an evidence treatment to clients
- Target A-CRA [ Time Frame: 14 weeks post intake ]Based on a review of recordings of actual client sessions is an indicator of whether or not clients received 10 or more of 12 specified treatment procedures within no less than seven treatment sessions.
- A-CRA Competence [ Time Frame: Monthly ]Based on review of a randomly selected session recording is an indicator of whether or not participants delivered at least one treatment procedure at or above the level of competence required as part of the certification process.
- Percent of days abstinent [ Time Frame: 6 months post-intake ]Based on client self report is the percentage of days during the past 90 days that clients reported not using any alcohol or other drugs.
- Pay-for-performance Cost-Effectiveness [ Time Frame: First six months of study ]The cost per unit of Target A-CRA, A-CRA Competene, and Percentage of Days Abstient in the experimental condition relative to the control condition.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01016704
|United States, Illinois|
|Lighthouse Institute, Chestnut Health Systems|
|Normal, Illinois, United States, 61761|
|Principal Investigator:||Bryan R Garner, Ph.D.||Chestnut Health Systems|